|
🐜
|
52620 Long-term safety and efficacy of secukinumab over 236 weeks in children and adolescents with severe chronic plaque psoriasis: Results of a double-blind, randomized controlled phase III trial
10 auth.
Shoba Ravichandran,
Andrzej Kaszuba,
Dorota Krasowska,
N. Magnolo,
Amita Bansal,
Swapnil S. Dahale,
...
R. Martin,
B. Paguet,
Philemon Papanastasiou,
K. Kingo
|
0 |
2024 |
0
🐜
|
